Onyema Ogbuagu, CROI 2022: Long-acting Lenacapavir in People with Multidrug Resistant HIV – Week 52 Results

Lenacapavir, a potent first-in-class inhibitor of HIV-1 capsid function, is in development for treatment and prevention of HIV-1 infection. Dr Onyema Ogbuagu (Yale School of Medicine, New Haven, CT, USA) discusses the ongoing phase 2/3 CAPELLA study, investigating lenacapavir in combination with an optimized background regimen treatment-experienced people with HIV-1, with multidrug-resistance and ongoing viremia. 

The abstract entitled: ‘Long-Acting Lenacapavir in People with Multidrug Resistant HIV-1: Week 52 Results’ (Abstract #496) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.

Questions:

1. What are the unmet needs of people living with HIV infection? (0:14)
2. What is the mechanism of action of lenacapavir and what are its potential advantages over existing HIV therapies? (1:21)
3. What were the aims, methodology and findings of the CAPELLA trial? (3:02)
4. What will be the next steps in the clinical development of lenacapavir in this indication? (7:57)

Disclosures: Onyema Ogbuagu is on advisory boards for Gilead Sciences and ViiV Healthcare and a speaker’s Bureau participant for Gilead Sciences.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of CROI 2022.